Testing a new medication to help people with PTSD

Plain-English translation of NCT07456696 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Read our Post Traumatic Stress Disorder research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called to see if it can help people with post-traumatic stress disorder (PTSD). You would receive either one of two doses of this medication or a placebo (an inactive pill that looks identical), given once a week for 4 weeks. Researchers will then follow you for 8 more weeks to see how you're doing.

PTSD is a serious condition, and while some treatments exist, they don't help everyone. This trial is testing whether this new treatment might offer another option for people who haven't had enough relief from existing medications or therapy.

Do you qualify?

You likely qualify if…

you have been diagnosed with PTSD that has lasted at least 6 months
you have already tried at least one PTSD medication or trauma-focused therapy
you are able to read, write, and speak well enough to complete interviews and questionnaires
you do not have other serious medical or mental health conditions that would interfere with the study

You likely don't qualify if…

you have another mental health disorder as your primary diagnosis
your weight or body mass index falls outside a certain healthy range
you cannot go at least 8 hours without using nicotine products
you have a current or past history of serious heart, blood vessel, or stroke-related conditions
you are taking medications or receiving therapies that would interfere with this study

What participation looks like

You would come in once a week for 4 weeks to receive an injection of either the new medication or a placebo. Then you would return for check-in visits over the next 8 weeks so the research team can monitor your symptoms and any side effects. Throughout the study, you'll complete questionnaires about how you're feeling and be asked about your PTSD symptoms.

AI-generated summary from trial data · Jun 11, 2026 · Not medical advice

Trial locations(32 sites)

United States

Del Sol Research, Tucson, Arizona

Preferred Research Partners, Little Rock, Arkansas

Kadima Neuropsychiatry, La Jolla, California

CalNeuro Research Group, Los Angeles, California

Catalina Research Institute, Montclair, California